Evidence map›Paper›PMID 34258392›Full record

ArticleOpen medicine (Warsaw, Poland)2021

Serum intact fibroblast growth factor 23 in healthy paediatric population.

Malgorzata Stanczyk, Slawomir Chrul, Krystyna Wyka, Marcin Tkaczyk

Open access · goldAbstract read
In one paragraph

Article in Open medicine (Warsaw, Poland), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed, 1 pooled it
1.3field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 1 synthesis or guideline pooled it, 11 citations in OpenAlex.

  1. Pooled it
  2. The Significance of Fibroblast Growth Factor 23 and 24,25-Dihydroxyvitamin D in Dent Disease Type 1.Clinical journal of the American Society of Nephrology : CJASN · 2026
    Article
  3. Article
  4. Article
  5. Emerging concepts on the FGF23 regulation and activity.Molecular and cellular biochemistry · 2025
    Review
  6. Article
  7. Article
  8. [Clinical study on growth impairment induced by oral glucocorticoids based on FGF23/Klotho homeostasis observations].Zhongguo dang dai er ke za zhi = Chinese journal of contemporary pediatrics · 2024
    Article
  9. Review
  10. Observational
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 1 country.

Malgorzata StanczykDepartment of Pediatrics, Immunology and Nephrology, Polish Mother's Memorial Hospital Research Institute, Rzgowska 281/289, Lodz 93-338, Poland.ORCID https://orcid.org/0000-0001-6613-1642
Slawomir ChrulDepartment of Pediatrics, Immunology and Nephrology, Polish Mother's Memorial Hospital Research Institute, Lodz 93-338, Poland.
Krystyna WykaDepartment of Pediatrics, Oncology and Hematology, Medical University of Lodz, Lodz, Poland.
Marcin TkaczykDepartment of Pediatrics, Immunology and Nephrology, Polish Mother's Memorial Hospital Research Institute, Lodz 93-338, Poland.
Medical University of Lodz · PLPolish Mother’s Memorial Hospital Research Institute · PL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionIt is believed that fibroblast growth factor 23 (FGF23) can become an early biomarker of chronic kidney disease progression. Data on FGF23 age dependency are inconsistent. We present the results of the cross-sectional study concerning FGF23 levels in healthy Polish children. MATERIAL AND

methodsThis study was conducted in 121 children aged 0-18 years. Kidney function and intact FGF23 levels in serum were assessed. Differences between age groups and according to gender were analysed.

resultsThe difference in FGF23 between age groups and according to gender was statistically insignificant. In the youngest and the oldest group, a trend to higher FGF23 levels was observed. FGF23 level in girls tended to be higher than boys, apart from the age group between 1 and 4 years. There was a negative correlation between eGFR and FGF23 (

conclusionsOur study supports the evidence that the FGF23 level in paediatric population is not age or sex dependent. The results can serve as a reference point under clinical conditions and for other studies on the topic.

Indexed as

childfibroblast growth factorsrenal insufficiency

Identifiers

PMID34258392
PMCPMC8262519
OpenAlexW3178886445

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.